Articles

Elsevier,

Journal of Prevention of Alzheimer's Disease, Volume 12, 1 September 2025

The TRAILBLAZER-ALZ 6 study found that a modified donanemab titration regimen significantly reduced ARIA-E frequency and severity compared to standard dosing, while maintaining similar amyloid reduction. Safety profiles were comparable between the two arms. The modified titration approach may help mitigate risks associated with amyloid-targeting therapies in early Alzheimer's disease.
Elsevier,

Endocrine Practice

Volume 31, Issue 9, Supplement, September 2025, Page S193

 

Evidence from preclinical research suggests that dysfunction in thyroid hormones may increase ?-amyloid levels and tau phosphorylation, 2 hallmark features of Alzheimer's Disease(AD). This study showed a strong association between hypothyroidism and AD mortality.

A youn g child watching anothether child demonstrating the use of a water filter
RELX

RELX Environmental Challenge 2025: four shortlisted projects to bring safe water and sanitation to communities around the world

The RELX Environmental Challenge 2025 shortlist features four innovative projects that provide sustainable access to safe water and improved sanitation.  The RELX Environmental Challenge prioritises replicable, scalable, sustainable and innovative solutions. They must also have practical applicability and involve local communities and other key stakeholders.

Elsevier,

Pharmacological Research, Volume 218, August 2025

This article describes the discovery and characterization of FJMU1887, a novel brain-penetrant small-molecule inhibitor of Galectin-3 (Gal-3) identified through an AI-driven drug discovery platform. FJMU1887 demonstrated potent anti-inflammatory effects, reduced Aβ pathology, and improved cognitive function in Alzheimer's disease mouse models, highlighting its therapeutic potential for the treatment of Alzheimer's disease.
Elsevier,

Pharmacological Research, Volume 218, August 2025

The article provides a comprehensive overview of the role of the endogenous detoxification system in the pathogenesis of age-related neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). It highlights epidemiological evidence linking environmental toxicant exposure to the onset and progression of these diseases, and discusses how dysfunction of detoxification pathways, including enzymes and transporters, can exacerbate neurodegenerative processes. The article also explores the potential of targeting nuclear receptor signaling pathways, such as the pregnane X receptor (PXR), as a promising therapeutic strategy to restore detoxification capacity and modify disease trajectories.
Elsevier,

Brain Research Bulletin, Volume 228, August 2025

This study investigated how repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training affects functional connectivity in both gray matter and white matter in patients with mild to moderate Alzheimer’s disease. Results showed that rTMS modulated activity in key brain regions, particularly within the limbic system, with changes in white matter connectivity correlating with cognitive improvements.
Elsevier,

The Lancet Regional Health - Southeast Asia, Volume 39, August 2025

using neuroimaging, authors try to collect evidence associating polluting cooking fuels with cognitive function impairement in rural aging Indians.
Elsevier,

Journal of Prevention of Alzheimer's Disease, Volume 12, 1 August 2025

The study found that long-duration and high-intensity walking were associated with reduced amyloid-beta accumulation over 4 years, with the greatest benefits seen in those who started walking earlier in life. However, walking activity was not linked to changes in tau deposition, neurodegeneration, or white matter hyperintensities.
Elsevier,

Journal of Prevention of Alzheimer's Disease, Volume 12, 1 August 2025

The article estimates the value-based price of a blood test for Alzheimer's disease pathology, finding it would be $290-$1150 in primary care and $450-$1950 in specialty care, projecting substantial cost savings.
Elsevier,

Journal of Pharmacology and Experimental Therapeutics, Volume 392, August 2025

This review discusses the dual role of amyloid-beta (Aβ) in Alzheimer's disease (AD). While Aβ accumulation is a hallmark of AD pathology, soluble Aβ also plays a neuroprotective role in regulating synaptic plasticity and memory. The review explores the potential of anti-Aβ immunotherapy as a treatment strategy, highlighting the need to balance targeting toxic Aβ species while preserving the physiological functions of Aβ.`

Pages